- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study: Safety Net ERs not at Disadvantage on Meeting Proposed Length-of-Stay Measures
The authors wrote that there is a concern that performance measures for EDs approved in 2008 by the National Quality Forum could result in safety-net hospitals being harmed if the measures are used in pay-for-performance programs. The fear is that safety net providers—which care for a disproportionate amount of Medicaid and uninsured patients—might be harmed by the 2 new measures, which look at time to discharge, transfer or held for observation and at time to inpatient admission.
Read more at: http://tinyurl.com/8acyoba
Source: Modern Healthcare
The study compared performance against criteria not in the NQF measures but ones used by other groups: 4 hours for time-to-discharge, transfer or observation, and 8 hours for time-to-admission.
Safety net hospital emergency departments are not at a disadvantage in terms of meeting the terms of proposed length-of-stay measures for patients both admitted and discharged, according to a new study published by the Journal of the American Medical Association.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
